Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
19.79
+0.87 (4.60%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Upstream Bio Employees
Upstream Bio had 52 employees as of December 31, 2024.
Employees
52
Change
n/a
Growth
n/a
Revenue / Employee
$52,365
Profits / Employee
-$2,116,519
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
UPB News
- 10 days ago - Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - GlobeNewsWire
- 4 weeks ago - Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 4 weeks ago - Upstream Bio, Inc. - Special Call - Seeking Alpha
- 5 weeks ago - Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - GlobeNewsWire
- 5 weeks ago - Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - GlobeNewsWire
- 2 months ago - Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 3 months ago - Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewsWire
- 4 months ago - Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewsWire